It is well established that patients with diabetes demonstrate higher susceptibility to pancreatic cancer and pancreatitis compared to non-diabetic individuals, and theoretically, sustained GLP-1 receptor activation induced by GLP-1RA therapy may potentially elevate pancreatic cancer risk [8]. This evidence concerns the gene GLP1R and familial pancreatic carcinoma.